Immunosuppressive MFAP2^+ cancer associated fibroblasts conferred unfavorable prognosis and therapeutic resistance in gastric cancer

[1]  M. Sy,et al.  Targeting type I collagen for cancer treatment , 2022, International journal of cancer.

[2]  Quan P. Ly,et al.  Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  R. Zhao,et al.  Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer , 2022, Theranostics.

[4]  X. Ying,et al.  Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy , 2021, World journal of gastrointestinal oncology.

[5]  G. Frühbeck,et al.  Decreased Levels of Microfibril-Associated Glycoprotein (MAGP)-1 in Patients with Colon Cancer and Obesity Are Associated with Changes in Extracellular Matrix Remodelling , 2021, International journal of molecular sciences.

[6]  Robert F. Gruener,et al.  oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data , 2021, Briefings Bioinform..

[7]  Xiao-Mei Yang,et al.  CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer , 2021, Oncogene.

[8]  B. Badgwell,et al.  Current treatment and recent progress in gastric cancer , 2021, CA: a cancer journal for clinicians.

[9]  N. Sun,et al.  PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-κB/IL8 pathway , 2021, Cell death discovery.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  M. Tsuboi,et al.  Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. , 2020, Lung cancer.

[12]  Wei Jiang,et al.  MFAP2 Promotes the Proliferation of Cancer Cells and Is Associated With a Poor Prognosis in Hepatocellular Carcinoma , 2020, Technology in cancer research & treatment.

[13]  Zemin Zhang,et al.  The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications , 2020, Cellular & Molecular Immunology.

[14]  Uri Alon,et al.  Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome , 2020, Nature Cancer.

[15]  K. Pietras,et al.  Heterogeneity of cancer‐associated fibroblasts: Opportunities for precision medicine , 2020, Cancer science.

[16]  Huazi Xu,et al.  Molecular structure and function of microfibrillar‐associated proteins in skeletal and metabolic disorders and cancers , 2020, Journal of cellular physiology.

[17]  D. Tuveson,et al.  DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. , 2020, Physiological reviews.

[18]  Wei Zhou,et al.  MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway , 2020, Oncogenesis.

[19]  Thea D. Tlsty,et al.  A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.

[20]  R. Salazar,et al.  Comparison and applicability of molecular classifications for gastric cancer. , 2019, Cancer treatment reviews.

[21]  Jiang-hong Zheng,et al.  CTHRC1 promotes wound repair by increasing M2 macrophages via regulating the TGF-β and notch pathways. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  Serge Haan,et al.  In search of definitions: Cancer‐associated fibroblasts and their markers , 2019, International journal of cancer.

[23]  J. Madore,et al.  Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. , 2019, Cancer cell.

[24]  M. Smyth,et al.  Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.

[25]  M. Tsuboi,et al.  Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. , 2018, Lung cancer.

[26]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[27]  R. Mitchell,et al.  Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner , 2018, QJM : monthly journal of the Association of Physicians.

[28]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[29]  G. Mills,et al.  Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype , 2018, Nature Communications.

[30]  H. Putter,et al.  Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[31]  H. Yao,et al.  CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness , 2018, Cell.

[32]  S. Tommasi,et al.  u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression , 2017, BMC Cancer.

[33]  Xiaodong Zhang,et al.  The biological function and significance of CD74 in immune diseases , 2017, Inflammation Research.

[34]  Yufang Shi,et al.  Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets , 2016, Nature Reviews Drug Discovery.

[35]  Song-Cheol Kim,et al.  CTHRC1 promotes angiogenesis by recruiting Tie2-expressing monocytes to pancreatic tumors , 2016, Experimental & Molecular Medicine.

[36]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[37]  F. Garrido,et al.  The urgent need to recover MHC class I in cancers for effective immunotherapy , 2016, Current opinion in immunology.

[38]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[39]  Insuk Sohn,et al.  Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery , 2014, PloS one.

[40]  D. Templeton,et al.  Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment , 2012, The Journal of Immunology.

[41]  M. Weller,et al.  Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression , 2011, Acta Neuropathologica.

[42]  N. Cho,et al.  Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial–mesenchymal transition-like state in breast cancer cells in vitro , 2010, Journal of Cell Science.

[43]  D. Sargent,et al.  Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. , 2010, JAMA.

[44]  Thomas Vierbuchen,et al.  Direct conversion of fibroblasts to functional neurons by defined factors , 2010, Nature.

[45]  Qiang Zhou,et al.  Expression of Macrophage Migration Inhibitory Factor by Neuroblastoma Leads to the Inhibition of Antitumor T Cell Reactivity In Vivo1 , 2008, The Journal of Immunology.

[46]  C. Earle,et al.  Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America , 2012, Gastric Cancer.

[47]  R. Mecham,et al.  The intracellular form of human MAGP1 elicits a complex and specific transcriptional response. , 2007, The international journal of biochemistry & cell biology.